The global Next Generation Sequencing (NGS) market is expected to grow significantly in the coming years. Valued at US$ 10.27 billion in 2024, it is projected to rise to US$ 12.51 billion by 2025 and reach approximately US$ 73.47 billion by 2034, growing at a robust compound annual growth rate (CAGR) of 21.74% during this period. This rapid growth is driven by the increasing demand for NGS in disease diagnosis, disease analysis, the development of new treatments, and advancements in gene and cell therapies.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5344
The Next Generation Sequencing (NGS) market involves products, services, and devices used for sequencing genetic materials, as well as the research and development associated with NGS technologies. NGS is a technique that identifies DNA or RNA sequences, enabling the investigation of genetic variations linked to diseases and other biological phenomena. This technology has transformed biological sciences, allowing labs to explore complex biological systems and perform a wide range of applications. Unlike traditional DNA sequencing, which lacks the depth needed to address today’s complex genomics challenges, NGS has filled this gap and become an essential tool for solving these problems.
In May 2022, Ultima Genomics, a new player in the DNA sequencing field, secured the largest private biotech investment in the United States. Along with advancements in omics-based diagnostics and cultured leather, several leading companies are focusing on gene and cell therapies.
In October 2024, MiLaboratories raised $10 million in Series A funding to revolutionize genomic research. The company’s Platforma.bio Software Development Kit, developed by its San Francisco-based team with an R&D unit in Bilbao, is changing the way biologists interpret genetic data, accelerating drug development, and improving related medical fields.
In October 2024, Illumina, a leading medical equipment manufacturer, introduced a new line of smaller, benchtop gene sequencers aimed at making sequencing more affordable and accessible to research and testing labs.
In October 2024, Illumina launched the MiSeq i100 Series of sequencing equipment, designed to enhance NGS capabilities. The new systems offer faster turnaround times and are more user-friendly, making them ideal for laboratories looking to streamline their sequencing processes.
In August 2023, as part of the Almac Group, Almac Diagnostic Services made an investment to expand Next Generation Sequencing (NGS) capabilities, providing BioPharma partners with broader access to advanced sequencing technologies.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/next-generation-sequencing-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5344
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The medical imaging market is witnessing rapid expansion worldwide, and Europe is emerging as a key contributor to this global… Read More
The global continuous glucose monitoring devices market size is calculated at USD 4.97 in 2024. Living with diabetes in Canada… Read More
The surgical sutures market in the United States is showing steady and promising growth, and here’s why! 👇 👵👴 An… Read More
Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More
Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More
Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More